Claris Lifesciences is a good buy: G Chokkalingam, Equinomics Research & Advisory Pvt Ltd

In a chat with ET Now, G Chokkalingam, Founder & Managing Director at Equinomics Research & Advisory Pvt Ltd, talks about the market. Excerpts:

ET Now: Any other top idea that perhaps you would have missed that you are recommending right now as a buy?

G Chokkalingam: Claris Lifesciences has miserably underperformed, but the fact is that it has good management. By selling the division, they rewarded their shareholders heavily. They have got a tie up with Japanese players and still they have 20% stake in the business. Moreover, it is a zero debt company.

Hence, if you combine the net cash with the valuation of the 20% stake with Japanese players, and then the business size, it is grossly undervalued. I am sure the company can give about 30% return in the next six months to 12 months. Hence, we suggest buying Claris Lifesciences.